Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 133

Sort by

Sort Order Select

Journal Articles

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Blood blood.2024025690.

https://doi.org/10.1182/blood.2024025690

Published: 2024

Includes: Supplemental data

Journal Articles

DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease

Benjamin G. Barwick, Robert M Chavez, Doris R. Powell, Yu Zhang, Mark Hamilton, Daniel Auclair, George Mulligan, Karen N Conneely, Jonathan J Keats, Paula M Vertino, Lawrence H. Boise, Sagar Lonial

Blood (2024) 144 (Supplement 1): 251.

https://doi.org/10.1182/blood-2024-201447

Published: 2024

Journal Articles

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

Marcella Kaddoura, J Erin Wiedmeier-Nutor, Vikas A. Gupta, Bachisio Ziccheddu, Suganti Shivaram, Hongwei Tang, Rodrigo Fonseca, Michael Durante, Shannon M Matulis, Tomas Jelinek, Ola Landgren, Constantine S Mitsiades, P. Leif Bergsagel, Esteban Braggio, Lawrence H. Boise, Rafael Fonseca, Shaji Kumar, Francesco Maura, Linda B. Baughn

Blood (2024) 144 (Supplement 1): 249.

https://doi.org/10.1182/blood-2024-204071

Published: 2024

Journal Articles

The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Blood (2024) 144 (Supplement 1): 4635.

https://doi.org/10.1182/blood-2024-205385

Published: 2024

Journal Articles

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Shannon M Matulis, Robert M Chavez, Rebecca Owens, Arun P Wiita, Mala Shanmugam, Ricardo De Matos Simoes, Constantine S Mitsiades, Nisha S. Joseph, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Vikas A. Gupta, Jonathan D. Licht, Benjamin G. Barwick, Lawrence H. Boise

Blood (2024) 144 (Supplement 1): 4663.

https://doi.org/10.1182/blood-2024-210441

Published: 2024

Journal Articles

Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma

Robert M Chavez, Doris R. Powell, Kiran Lakhani, John Attelah, Erin Flynt, Terry Connolly, Mark Hamilton, George Mulligan, Daniel Auclair, Jonathan Keats, Paula M Vertino, Lawrence H. Boise, Sagar Lonial, Karen N Conneely, Benjamin G. Barwick

Blood (2024) 144 (Supplement 1): 1359.

https://doi.org/10.1182/blood-2024-210929

Published: 2024

Journal Articles

Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma

Holly Lee, Sungwoo Ahn, Mansour Poorebrahim, David Jung, Sacha Benaoudia, Noémie Leblay, Francesco Maura, Lawrence H. Boise, Paola Neri, Nizar J. Bahlis

Blood (2024) 144 (Supplement 1): 1892.

https://doi.org/10.1182/blood-2024-211979

Published: 2024

Journal Articles

KDM6A regulates immune response genes in multiple myeloma

Daphné Dupéré-Richer, Alberto Riva, Benjamin G. Barwick, Sayantan Maji, Heidi Casellas Román, Jianping Li, Umasankar De, Amin Sobh, Gabrielle Quickstad, Crissandra Piper, Marta Kulis, Teresa Ezponda, José Ignacio Martín-Subero, Giovanni Tonon, Weizhou Zhang, Constantine S. Mitsiades, Lawrence H. Boise, Richard L. Bennett, Jonathan D. Licht

Blood (2024) 144 (14): 1508–1520.

https://doi.org/10.1182/blood.2024024518

Published: 2024

Includes: Supplemental data

Journal Articles

NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome

Blood (2024) 144 (3): 283–295.

https://doi.org/10.1182/blood.2023022859

Published: 2024

Includes: Supplemental data

Journal Articles

TP53 function over forms in multiple myeloma

Paola Neri, Lawrence H. Boise

Blood (2024) 143 (13): 1202–1204.

https://doi.org/10.1182/blood.2023023487

Published: 2024

Journal Articles

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

Noémie Leblay, Sungwoo Ahn, Rémi Tilmont, Mansour Poorebrahim, Ranjan Maity, Holly Lee, Elie Barakat, Jean-Baptiste Alberge, Sarthak Sinha, Arzina Jaffer, Benjamin G. Barwick, Lawrence H. Boise, Nizar Bahlis, Paola Neri

Blood (2024) 143 (1): 42–56.

https://doi.org/10.1182/blood.2023020276

Published: 2024

Includes: Supplemental data

Journal Articles

Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)

Nisha S. Joseph, Jonathan L. Kaufman, Sara Dicamillo, Danielle Roberts, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sagar Lonial, Ajay K. Nooka

Blood (2023) 142 (Supplement 1): 647.

https://doi.org/10.1182/blood-2023-187339

Published: 2023

Journal Articles

Discovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma

Blood (2023) 142 (Supplement 1): 465.

https://doi.org/10.1182/blood-2023-182578

Published: 2023

Journal Articles

Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells

Mansour Poorebrahim, Holly Lee, Sacha Benaoudia, Ranjan Maity, Sungwoo Ahn, Noémie Leblay, Elie Barakat, Remi Tilmont, Douglas Mahoney, Lawrence H. Boise, Paola Neri, Nizar J Bahlis

Blood (2023) 142 (Supplement 1): 454.

https://doi.org/10.1182/blood-2023-189747

Published: 2023

Journal Articles

SDC2 Expression Is Increased in Myeloma Cells in Response to Loss of Pro-Survival Surface Proteins, CD28 and CD86

Veronica Canarte, Tyler Moser-Katz, Catherine Gavile, Benjamin G. Barwick, Kelvin P. Lee, Lawrence H. Boise

Blood (2023) 142 (Supplement 1): 3299.

https://doi.org/10.1182/blood-2023-190453

Published: 2023

Journal Articles

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

Jonathan L. Kaufman, Nisha S. Joseph, Vikas A. Gupta, Sara Dicamillo, Danielle Roberts, Craig C. Hofmeister, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Lawrence H. Boise

Blood (2023) 142 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2023-181783

Published: 2023

Journal Articles

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

Olga Dashevsky, Sara Gandolfi, Olli Dufva, Ricardo De Matos Simoes, Jani Huuhtanen, Benjamin G. Barwick, Ryosuke Shirasaki, Michal Sheffer, Aidan Culhane, Jonathan D. Licht, Christine-Ivy Liacos, Evangelos Terpos, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Lawrence H. Boise, Francisca Vazquez, Matti Kankainen, Satu Mustjoki, Constantine S Mitsiades

Blood (2023) 142 (Supplement 1): 6842.

https://doi.org/10.1182/blood-2023-189570

Published: 2023

Journal Articles

Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders

Blood (2022) 140 (Supplement 1): 244–245.

https://doi.org/10.1182/blood-2022-169558

Published: 2022

Journal Articles

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12997.

https://doi.org/10.1182/blood-2022-169920

Published: 2022

Journal Articles

Gene Editing and Multi-Omics Reveal Novel Metabolic Vulnerabilities in t(4;14)-Associated Multiple Myeloma

Amin Sobh, Charlotte L Kaestner, Alberto Riva, Karthik Vasan, Alisha Patel, Greeshma Surapaneni, Janai Poullard, Elena Encinas, Richard Lynn Bennett, Constantine S. Mitsiades, Lawrence H. Boise, Navdeep S. Chandel, Jonathan D. Licht

Blood (2022) 140 (Supplement 1): 5911–5912.

https://doi.org/10.1182/blood-2022-169256

Published: 2022

NARROW

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

DNA Methylation Analysis of Commpass Reveals Distinct Epigenetic Programs of High-Risk Disease

Genomic Determinants of Clinical Outcomes in Multiple Myeloma with t(11;14)(CCND1;IGH) Treated with Venetoclax

The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Ectopic NSD2 Remodels H3K36me2 and DNA Methylation to Promote Oncogenic Gene Expression in Multiple Myeloma

Tumor Intrinsic and Antigen-Independent Resistance Mechanisms to Bispecific T Cell Engagers in Multiple Myeloma

KDM6A regulates immune response genes in multiple myeloma

NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome

TP53 function over forms in multiple myeloma

Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency

Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)

Discovery and Development of CD70 As a Cellular Therapy Target in High Risk Multiple Myeloma

Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells

SDC2 Expression Is Increased in Myeloma Cells in Response to Loss of Pro-Survival Surface Proteins, CD28 and CD86

Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma

Natural Killer Cells Are Active Against Myeloma, Leukemia or Lymphoma Cells with Loss of Tumor Suppressor Genes

Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders

IMiDs Synergize with EP300 Inhibition to Disrupt the Ikzf/MYC/IRF4 Axis in Multiple Myeloma

Gene Editing and Multi-Omics Reveal Novel Metabolic Vulnerabilities in t(4;14)-Associated Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only